KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Working Capital: 2014-2020

Historic Change in Working Capital for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2020 value amounting to $6.7 million.

  • Aurinia Pharmaceuticals' Change in Working Capital fell 27.58% to $6.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$6.7 million, marking a year-over-year decrease of 130.33%. This contributed to the annual value of -$2.1 million for FY2019, which is 135.48% down from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Change in Working Capital of $6.7 million as of Q3 2020, which was up 1,113.29% from -$662,000 recorded in Q2 2020.
  • In the past 5 years, Aurinia Pharmaceuticals' Change in Working Capital ranged from a high of $10.8 million in Q4 2018 and a low of -$11.3 million during Q4 2019.
  • In the last 3 years, Aurinia Pharmaceuticals' Change in Working Capital had a median value of $849,000 in 2019 and averaged $1.7 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Change in Working Capital skyrocketed by 3,727.69% in 2019, and later tumbled by 247.06% in 2020.
  • Over the past 3 years, Aurinia Pharmaceuticals' Change in Working Capital (Quarterly) stood at $10.8 million in 2018, then tumbled by 203.90% to -$11.3 million in 2019, then declined by 27.58% to $6.7 million in 2020.
  • Its last three reported values are $6.7 million in Q3 2020, -$662,000 for Q2 2020, and -$1.4 million during Q1 2020.